Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
BörsenkürzelVXRT
Name des UnternehmensVaxart Inc
IPO-datumMar 17, 1980
CEOMr. Steven (Steve) Lo
Anzahl der mitarbeiter105
WertpapierartOrdinary Share
GeschäftsjahresendeMar 17
Addresse170 Harbor Way, Suite 300
StadtSOUTH SAN FRANCISCO
BörseUS 'Other OTC' and Grey Market
LandUnited States of America
Postleitzahl94080
Telefon16505503500
Websitehttps://vaxart.com/
BörsenkürzelVXRT
IPO-datumMar 17, 1980
CEOMr. Steven (Steve) Lo
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten